Like most biotechs, Inovio Pharmaceuticals (NASDAQ: INO), a pre-revenue vaccine developer, had a rather poor showing in December. Specifically, it lost exactly a quarter of its value last month, according to data from S&P Global Market Intelligence.
The upside is that Inovio's year-end sell-off wasn't triggered by a clinical or regulatory setback. Rather, its shares simply fell in tandem with the broader market. So, not surprisingly, they've also come charging back with the market's sharp reversal over the first two weeks of the new year -- gaining a healthy 21% year to date.
Image Source: Getty Images.
The particularly noteworthy aspect of last month's downturn is the fact that Inovio -- and, really, all biotechs -- plummeted regardless of events on the ground. As proof, Inovio kicked off December with a solid clinical update: the start of the company's phase 2 cancer trial with big pharma partner AstraZeneca (NYSE: AZN).
Turning to the details, the two companies announced on Dec. 4 that the first patient had been dosed in a mid-stage trial designed to assess Astra's MEDI0457 (formerly INO-3112 prior to the licensing deal) in combination with the checkpoint inhibitor durvalumab across a diverse array of cancers associated with the human papilloma virus. This upbeat clinical update failed to save Inovio's stock from the ravages of the moody market, however.
Inovio's stock appears set to continue its recent rally in the days and weeks ahead. After all, this clinical-stage biotech sports a promising late-stage cervical dysplasia vaccine known as VGX-3100, which has the potential to generate hundreds of millions in sales over the next decade, according to EvaluatePharma.
That said, Inovio's stock will probably remain at the mercy of the broader market until the company finally transforms into a commercial-stage operation and begins to generate profits on a consistent basis. Shareholders should, therefore, expect a good deal of volatility going forward, despite the monstrous commercial opportunity offered by the company's portfolio of high-value vaccine candidates.
More From The Motley Fool
- 10 Best Stocks to Buy Today
- 3 Stocks That Are Absurdly Cheap Right Now
- 5 Warren Buffett Principles to Remember in a Volatile Stock Market
- The $16,728 Social Security Bonus You Cannot Afford to Miss
- The Must-Read Trump Quote on Social Security
- 10 Reasons Why I'm Selling All of My Apple Stock